144 related articles for article (PubMed ID: 22426455)
1. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.
Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW
Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455
[TBL] [Abstract][Full Text] [Related]
2. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
3. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
4. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
[TBL] [Abstract][Full Text] [Related]
5. Expeditious Generation of Biparatopic Common Light Chain Antibodies
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2020; 11():606878. PubMed ID: 33424853
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
7. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
8. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
[TBL] [Abstract][Full Text] [Related]
9. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
10. Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.
Godar M; Morello V; Sadi A; Hultberg A; De Jonge N; Basilico C; Hanssens V; Saunders M; Lambrecht BN; El Khattabi M; de Haard H; Michieli P; Blanchetot C
Sci Rep; 2016 Aug; 6():31621. PubMed ID: 27546726
[TBL] [Abstract][Full Text] [Related]
11. A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models.
DaSilva JO; Yang K; Perez Bay AE; Andreev J; Ngoi P; Pyles E; Franklin MC; Dudgeon D; Rafique A; Dore A; Delfino FJ; Potocky TB; Babb R; Chen G; MacDonald D; Olson WC; Thurston G; Daly C
Clin Cancer Res; 2020 Mar; 26(6):1408-1419. PubMed ID: 31848185
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
[TBL] [Abstract][Full Text] [Related]
13. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.
Kamat V; Donaldson JM; Kari C; Quadros MR; Lelkes PI; Chaiken I; Cocklin S; Williams JC; Papazoglou E; Rodeck U
Cancer Biol Ther; 2008 May; 7(5):726-33. PubMed ID: 18424917
[TBL] [Abstract][Full Text] [Related]
14. A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.
Shi SY; Lu YW; Liu Z; Stevens J; Murawsky CM; Wilson V; Hu Z; Richards WG; Michaels ML; Zhang J; Yan W; Li Y
J Biol Chem; 2018 Apr; 293(16):5909-5919. PubMed ID: 29483191
[TBL] [Abstract][Full Text] [Related]
15. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system.
Asano R; Nakayama M; Kawaguchi H; Kubota T; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
FEBS J; 2012 Jan; 279(2):223-33. PubMed ID: 22074399
[TBL] [Abstract][Full Text] [Related]
16. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
[TBL] [Abstract][Full Text] [Related]
17. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
[TBL] [Abstract][Full Text] [Related]
18. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
[TBL] [Abstract][Full Text] [Related]
19. A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms.
Stefano JE; Lord DM; Zhou Y; Jaworski J; Hopke J; Travaline T; Zhang N; Wong K; Lennon A; He T; Bric-Furlong E; Cherrie C; Magnay T; Remy E; Brondyk W; Qiu H; Radošević K
J Biol Chem; 2020 Dec; 295(52):18379-18389. PubMed ID: 33122192
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]